News coverage about Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has trended somewhat positive this week, according to Accern Sentiment. Accern ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Adamis Pharmaceuticals Corporation earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave media headlines about the specialty pharmaceutical company an impact score of 45.6049796502328 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media headlines that may have effected Accern Sentiment’s analysis:
A number of research firms recently issued reports on ADMP. Raymond James Financial, Inc. began coverage on Adamis Pharmaceuticals Corporation in a report on Tuesday, September 12th. They issued an “outperform” rating and a $7.00 price target for the company. Maxim Group reaffirmed a “buy” rating and issued a $13.00 price target on shares of Adamis Pharmaceuticals Corporation in a report on Monday, August 21st. ValuEngine cut Adamis Pharmaceuticals Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. Finally, B. Riley reissued a “buy” rating and set a $9.50 price objective on shares of Adamis Pharmaceuticals Corporation in a report on Wednesday, October 4th.
Shares of Adamis Pharmaceuticals Corporation (ADMP) remained flat at $5.40 during mid-day trading on Friday. The stock had a trading volume of 434,977 shares. The stock’s 50 day moving average price is $5.24 and its 200-day moving average price is $4.76. Adamis Pharmaceuticals Corporation has a 52-week low of $2.50 and a 52-week high of $6.45. The stock’s market cap is $169.30 million.
ILLEGAL ACTIVITY WARNING: “Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Receives News Impact Rating of 0.14” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2017/10/28/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-adamis-pharmaceuticals-corporation-admp-share-price.html.
About Adamis Pharmaceuticals Corporation
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Ratings for Adamis Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.